Trading ideas: CBH, Sunway, Mudajaya, NexG, NationGate, iCents, Zetrix, Saliran, Berjaya, SunCon
CBH Engineering Holding Bhd has secured a contract worth RM172mn from an undisclosed client to build a substation's electrical supply system at a proposed data centre in Selangor.
Sunway Bhd and its Singapore-based JV partner, Sing Holdings Residential Pte Ltd, have secured a residential development project worth RM2.3bn in Chuan Grove, Singapore.
Mudajaya Group Bhd said its Indian unit RKM Powergen has been cleared by the High Court of Madras in a case linked to the alleged fraudulent acquisition of the Fatehpur East Coal Block in Chhattisgarh, allocated in 2008.
NexG Bhd has secured a six-month contract extension from the Home Affairs Ministry to continue supplying passport chips to the Immigration Department.
Nationgate Holdings Bhd said the recent raid by the Malaysian Anti-Corruption Commission on its wholly-owned subsidiary is not expected to have a significant impact on the group's financial performance or operations — for the time being.
iCents Group Holdings Bhd is optimistic about achieving double-digit revenue growth in the near term, driven by strong demand for its services and contributions from its manufacturing segment.
Kumpulan Wang Persaraan Diperbadankan has ceased to be a substantial shareholder in Zetrix AI Bhd after disposing of nearly eight million shares in the company earlier this week.
Saliran Group Bhd has appointed Yong Wai Kin, the company's chief financial officer, as executive director of the company.
Tan Sri Lim Kuang Sia, founder and group managing director of Kossan Rubber Industries Bhd , and his brother Lim Kuang Wang are no longer substantial shareholders of Berjaya Corp Bhd.
The Employees Provident Fund has ceased to be a substantial shareholder in Sunway Construction Group Bhd .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. 'This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment,' said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. 'We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.' About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media) Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)
Malaysia Sun
4 hours ago
- Malaysia Sun
India's semiconductor vision gathers momentum with 3nm chip design and talent development initiatives
New Delhi [India], July 25 (ANI): India is home to nearly 20 per cent of the world's chip design engineers and building on this strong talent base, the government is facilitating the development of a complete semiconductor ecosystem in India, Union Minister of State for Electronics and Information Technology, Jitin Prasada, informed Lok Sabha on Friday. Leading semiconductor companies have established chip design and research centers in India. A 3nm semiconductor chip designed in India was recently unveiled, the minister said. It showcases the technical capabilities of Indian engineers and importance of Indian design centres in global semiconductor industry. To foster talent development in the semiconductor chip design, the Government has launched several initiatives, such as, new curriculum by All India Council for Technical Education (AICTE) for VLSI Design and Technology, Integrated Circuit (IC) manufacturing; developing 85,000 skilled manpower in semiconductor design sector & providing EDA tools to design semiconductor chips; 45,000+ students from 100 institutions enrolled so far; Besides, a Skilled Manpower Advanced Research and Training (SMART) Lab at NIELIT Calicut is being undertaken to train 1 lakh engineers nation-wide with 44,000+ engineers already trained; collaboration with industry and universities such as Lam Research, IBM and Purdue University. India is leveraging its large talent pool, global semiconductor design companies are now rapidly expanding their workforce in India to design cutting-edge chips. Under Semicon India programme, a total outlay of Rs 76,000 crore was approved for catalysing semiconductor and display manufacturing ecosystem in India. Six (6) semiconductor manufacturing and 22 design-linked incentive (DLI) projects have been approved 72 companies are provided chip design infrastructure such as EDA tools & FPGA (Field Programmable Gate Array) boards from Synopsys, Cadence, Siemens, etc. Access to the Post Silicon Validation and Testing and Packaging Support is also being provided, the minister noted. (ANI)
The Sun
4 hours ago
- The Sun
India-UK trade deal signals shift in market openness, eyes EU-US pacts
NEW DELHI: India's trade deal with Britain is a sign of New Delhi's new gradual shift to opening up its markets while shielding crucial sectors from competition and could be its template for future agreements, government officials and analysts said on Friday. Signed on Thursday and hailed by Prime Minister Narendra Modi as 'a blueprint for our shared prosperity', the deal with the UK represents India's biggest ever strategic partnership with an advanced economy. It comes at a time rising global trade tensions and at a pivotal moment for India's historically protectionist trade strategy, as the Asian giant looks to strike similar deals with partners including the EU, U.S., and New Zealand. Under the pact, India notably agreed to cut tariffs on imported British vehicles, opening up competition for a domestic industry that makes up nearly 7% of the Indian economy. 'This is a policy shift, especially as India has long used high tariffs to protect domestic manufacturers,' Ajay Srivastava, founder of Global Trade Research Initiative and a former Indian trade negotiator, told Reuters. The easing of its protectionist stance also applies to government procurement and pharmaceuticals and will likely be replicated in deals with Brussels and Washington, he added. But it remains a cautious shift. Under the UK deal, auto imports will be capped under a quota system to shield local manufacturers, and tariff reductions will be gradual. India has committed to reducing auto tariffs from over 100% to 10% over 15 years, within an annual import quota starting at 10,000 units and rising to 19,000 in year five. Tariff reductions on whisky and other goods will also be phased over several years to allow domestic industries to adjust. RED LINES India has stuck to its red lines in the deal, making no concessions on agricultural items such as apples and walnuts or dairy products including cheese and whey. 'There is no question of opening up the agriculture or dairy sector in any trade negotiation — be it with the EU, Australia, or even the U.S.,' a senior Indian official said. The calibrated strategy aims to leverage trade for economic growth, the official said, but the government will continue to shield millions of Indians dependent upon subsistence farming and low-margin work. Indian farmers are eyeing broadened access to the UK's $37.5 billion agriculture market under the deal. And Indian exporters will benefit from zero tariffs on goods including textiles, footwear, gems, furniture, auto parts, machinery, and chemicals. 'With zero tariffs, India's garment exports to the UK could double in three years,' said N. Thirukkumaran, general secretary of the Tiruppur Exporters Association. 'This also paves the way for the EU agreement, which could bring even bigger gains,' he added. But the strategy could face a major test in negotiations with U.S. President Donald Trump's administration, which has used the threat of steep tariffs to pressure trading partners into making concessions. Trade Minister Piyush Goyal told Reuters on Thursday that India is also hopeful of reaching a trade agreement with Washington that includes 'special and preferred treatment'. But the U.S. is pushing for greater access to India's agricultural and dairy markets. - Reuters
